SearchSkip to Search Results
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder CancerDownload
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
Poxviruses, such as vaccinia virus (VACV) and myxoma virus (MYXV), actively modulate various cellular structures and functions to ensure effective replication and transmission. In the contrary, cells use several restriction mechanisms to mitigate these viruses. This evolutionary relationship is...
Breast cancer (BrCa) is the most common cancer and the leading cause of cancer-related deaths in women worldwide. Current therapies for BrCa are insufficient to cure metastatic disease and are often associated with debilitating side effects that severely deteriorate the quality of patients’...
Smallpox was eradicated using vaccinia viruses (VACV) as vaccines, including Dryvax, a calf-lymph vaccine derived from the New York City Board of Health (NYCBH) strain, and TianTan, a chicken egg cultured vaccine used exclusively in China. To take advantage of the next generation sequencing...
Vaccinia virus DNA polymerase and ribonucleotide reductase: their role in replication, recombination and drug resistanceDownload
Despite the eradication of smallpox, poxviruses continue to cause human disease around the world. At the core of poxvirus replication is the efficient and accurate synthesis and repair of the viral genome. The viral DNA polymerase is critical for these processes. Acyclic nucleoside phosphonate...